President & CEO
Tim Scott serves as president and CEO and a member of the Board of Directors of Biocom, the state’s leading life science advocate. Under his leadership, Biocom works on behalf of its members to build meaningful connections and gain valuable insights through Conferences & Events, deliver access to Funding & Partnering opportunities, provide Group Purchasing solutions that drive efficiency and savings, champion Policy & Advocacy that protects and advances the innovation ecosystem, and strengthen talent pipelines through Workforce Development. Tim oversees a team of 75 across offices in San Diego, Los Angeles, the San Francisco Bay Area, Sacramento, Washington, D.C. and Tokyo, collaborating with engaged boards to advance innovative benefits for members so they can advance medicines and medtech to address unmet medical needs.
With more than 20 years of entrepreneurial experience in biotech and pharmaceutical development, Mr. Scott previously led AustinPx, co-founded TEGA Therapeutics, and co-founded Pharmatek Laboratories, which was acquired by Catalent Pharma Solutions. He has also supported numerous spinouts from UC San Diego, including Zacharon Pharmaceuticals (acquired by BioMarin) and DTx (acquired by Novartis).
An active community leader, Mr. Scott serves on the boards of Avelas Biosciences and Rady Children’s Institute for Genomic Medicine. He is a trustee for the University of San Diego, the La Jolla Playhouse, Green Foundation for Earth Sciences at Scripps Institute of Oceanography and chairs the UC San Diego’s Dean’s Advisory Council for the Division of Biological Sciences.
Mr. Scott holds a B.A. in Biochemistry from UC San Diego and a J.D. from the University of San Diego. He is a member of the California Bar.